Published in Case Rep Hematol on December 26, 2012
Acquired "storage pool disease" of platelets associated with circulating antiplatelet antibodies. Am J Med (1974) 1.40
Activation of caspase-3 and c-Jun NH2-terminal kinase-1 signaling pathways in tamoxifen-induced apoptosis of human breast cancer cells. Cancer Res (2000) 1.27
Patients with a prolonged bleeding time and normal aggregation tests may have storage pool deficiency: studies on one hundred six patients. Blood (1987) 1.18
Platelet aggregation testing in platelet-rich plasma: description of procedures with the aim to develop standards in the field. Am J Clin Pathol (2005) 1.14
A flow cytometric assay using mepacrine for study of uptake and release of platelet dense granule contents. Br J Haematol (1995) 0.98
Mepacrine, a tool for investigating the 5-hydroxytryptamine organelles of blood platelets by fluorescence microscopy. J Lab Clin Med (1977) 0.91
Tamoxifen promotes superoxide production in platelets by activation of PI3-kinase and NADPH oxidase pathways. Thromb Res (2011) 0.90
Tamoxifen stimulates calcium entry into human platelets. J Cardiovasc Pharmacol (2007) 0.89
Anti-thrombotic effects of selective estrogen receptor modulator tamoxifen. Thromb Haemost (2011) 0.86
The effects of tamoxifen and its metabolites on platelet function and release of reactive oxygen intermediates. J Pharmacol Exp Ther (2004) 0.83
Correlation between prolonged bleeding time and depletion of platelet dense granule ADP in patients with myelodysplastic and myeloproliferative disorders. J Lab Clin Med (1984) 0.83
Role of raloxifene on platelet metabolism and plasma lipids. Eur J Clin Invest (2008) 0.83
A novel role for tamoxifen in the inhibition of human platelets. Transl Res (2010) 0.81
A flow cytometric assay for the study of dense granule storage and release in human platelets. Platelets (1999) 0.80
Acquired storage pool deficiency with increased platelet-associated IgG. Report of five cases. Am J Med (1980) 0.79
Enzymes and receptors of prostaglandin pathways with arachidonic acid-derived versus eicosapentaenoic acid-derived substrates and products. J Biol Chem (2007) 2.10
Murine prolylcarboxypeptidase depletion induces vascular dysfunction with hypertension and faster arterial thrombosis. Blood (2011) 1.86
Factor XII stimulates ERK1/2 and Akt through uPAR, integrins, and the EGFR to initiate angiogenesis. Blood (2010) 1.73
Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator. J Biol Chem (2002) 1.67
Prolylcarboxypeptidase regulates food intake by inactivating alpha-MSH in rodents. J Clin Invest (2009) 1.63
Prolylcarboxypeptidase promotes angiogenesis and vascular repair. Blood (2013) 1.54
Deletion of murine kininogen gene 1 (mKng1) causes loss of plasma kininogen and delays thrombosis. Blood (2007) 1.48
Recombinant prolylcarboxypeptidase activates plasma prekallikrein. Blood (2004) 1.37
In vivo roles of factor XII. Blood (2012) 1.37
Anti-c5a ameliorates coagulation/fibrinolytic protein changes in a rat model of sepsis. Am J Pathol (2002) 1.33
Bradykinin B2 receptor knockout mice are protected from thrombosis by increased nitric oxide and prostacyclin. Blood (2006) 1.24
Factor XII interacts with the multiprotein assembly of urokinase plasminogen activator receptor, gC1qR, and cytokeratin 1 on endothelial cell membranes. Blood (2002) 1.19
Thrombotic microangiopathy in haematopoietic stem cell transplantation: diagnosis and treatment. Drugs (2009) 1.18
The preparation and characterization of novel peptide antagonists to thrombin and factor VIIa and activation of protease-activated receptor 1. J Pharmacol Exp Ther (2004) 1.17
D-dimer, P-selectin, and microparticles: novel markers to predict deep venous thrombosis. A pilot study. Thromb Haemost (2005) 1.17
Platelet aggregation testing in platelet-rich plasma: description of procedures with the aim to develop standards in the field. Am J Clin Pathol (2005) 1.14
Increased platelet and microparticle activation in HIV infection: upregulation of P-selectin and tissue factor expression. J Acquir Immune Defic Syndr (2012) 1.11
Identification of prolyl carboxypeptidase as an alternative enzyme for processing of renal angiotensin II using mass spectrometry. Am J Physiol Cell Physiol (2013) 1.10
Ordered adsorption of coagulation factor XII on negatively charged polymer surfaces probed by sum frequency generation vibrational spectroscopy. Anal Bioanal Chem (2007) 1.07
Platelet-derived S100 family member myeloid-related protein-14 regulates thrombosis. J Clin Invest (2014) 1.06
Plasma prekallikrein: a risk marker for hypertension and nephropathy in type 1 diabetes. Diabetes (2003) 1.06
A functional thrombin receptor (PAR1) is expressed on bone-derived prostate cancer cell lines. Urology (2002) 1.05
Detection of amide I signals of interfacial proteins in situ using SFG. J Am Chem Soc (2003) 1.05
Factor XII: what does it contribute to our understanding of the physiology and pathophysiology of hemostasis & thrombosis. Thromb Res (2010) 0.98
Interaction of thrombin with PAR1 and PAR4 at the thrombin cleavage site. Biochemistry (2007) 0.97
AbetaPP/APLP2 family of Kunitz serine proteinase inhibitors regulate cerebral thrombosis. J Neurosci (2009) 0.97
Heparan sulfate modulates kinin release by Trypanosoma cruzi through the activity of cruzipain. J Biol Chem (2001) 0.96
Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis. Curr Opin Hematol (2007) 0.95
Angiotensin 1-7 and Mas decrease thrombosis in Bdkrb2-/- mice by increasing NO and prostacyclin to reduce platelet spreading and glycoprotein VI activation. Blood (2013) 0.94
Myeloperoxidase interacts with endothelial cell-surface cytokeratin 1 and modulates bradykinin production by the plasma Kallikrein-Kinin system. Am J Pathol (2007) 0.93
Identification of prolylcarboxypeptidase as the cell matrix-associated prekallikrein activator. FEBS Lett (2002) 0.92
Mapping the interaction between high molecular mass kininogen and the urokinase plasminogen activator receptor. J Biol Chem (2004) 0.90
Mechanisms of Arg-Pro-Pro-Gly-Phe inhibition of thrombin. Am J Physiol Heart Circ Physiol (2003) 0.90
The relative priority of prekallikrein and factors XI/XIa assembly on cultured endothelial cells. J Biol Chem (2003) 0.88
Assembly and activation of the plasma kallikrein/kinin system: a new interpretation. Int Immunopharmacol (2002) 0.86
Mapping the interaction of bradykinin 1-5 with the exodomain of human protease activated receptor 4. FEBS Lett (2005) 0.86
The plasma kallikrein/kinin and renin angiotensin systems in blood pressure regulation in sepsis. J Endotoxin Res (2004) 0.85
Synthesis of novel peptide inhibitors of thrombin-induced platelet activation. Chem Biol Drug Des (2006) 0.83
Factor VLeiden inhibits fibrinolysis in vivo. Circulation (2004) 0.83
Oral thrombostatin FM19 inhibits prostate cancer. Thromb Haemost (2010) 0.82
The Williams-Beuren Syndrome-a window into genetic variants leading to the development of cardiovascular disease. PLoS Genet (2012) 0.81
Streptococcal inhibitor of complement-mediated lysis (SIC): an anti-inflammatory virulence determinant. Microbiology (2010) 0.79
Oscar D. Ratnoff: a man for all seasons. Thromb Haemost (2010) 0.79
Homonymous hemianopia caused by occipital lobe infarction in heparin-induced thrombocytopenia and thrombosis syndrome. J Neuroophthalmol (2005) 0.79
Thrombosis in flowing blood. Blood (2009) 0.78
Sweet and sticky: diabetic platelets, enhanced reactivity, and cardiovascular risk. J Am Coll Cardiol (2007) 0.77
Why do we want to know how factor XII levels are modulated? Thromb Res (2009) 0.76
Domain 2 of uPAR regulates single-chain urokinase-mediated angiogenesis through β1-integrin and VEGFR2. Am J Physiol Heart Circ Physiol (2013) 0.76
Hematology grants workshop. Hematology Am Soc Hematol Educ Program (2002) 0.75
Laser-light scattering, a new method for continuous monitoring of platelet activation in circulating fluid. J Lab Clin Med (2003) 0.75
Thrombostatin, a bradykinin metabolite, reduces platelet activation in a model of arterial wall injury. Cardiovasc Res (2002) 0.75
The physiologic basis of assembly and activation of the plasma kallikrein/kinin system. Thromb Haemost (2004) 0.75